Mechanisms such as ketamine’s impact on AMPA receptors, its influence on BDNF and Trkβ signaling pathways, as well as the enhancing effect of psychedelics on neuroplasticity through the 5-HT2AR, all contribute to synaptic changes associated with depression and antidepressant effects. The gene discussed is BDNF; the disease is major depressive disorder.